干预固有免疫反应治疗糖尿病心肌病的研究进展  

Research Progress of Intervening Innate Immune Response in Treatment of Diabetic Cardiomyopathy

作　　者：周登双 刘嫚琪 吴子君 吴铿 ZHOU Dengshuang;LIU Manqi;WU Zijun;WU Keng(Graduate School,Guangdong Medical University,Zhanjiang 524000,China;Department of Cardiovascular Medicine,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)

机构地区：[1]广东医科大学研究生院,广东湛江524000 [2]广东医科大学附属医院心血管内科,广东湛江524000

出　　处：《医学综述》2022年第12期2453-2459,共7页Medical Recapitulate

基　　金：国家自然科学基金(81670348)。

摘　　要：糖尿病心肌病(DbCM)是由胰岛素分泌不足和(或)或胰岛素抵抗伴随糖脂代谢紊乱诱发的持续性低度炎症的代谢性心肌病,最终发展为心力衰竭。我国该疾病发病率逐年上升,且临床应用的药物疗效十分有限。随着相关的深入研究,发现由固有免疫反应介导的微血管功能障碍和心肌细胞异常凋亡加速了DbCM的进展,且干预固有免疫反应可以减轻糖尿病引起的心功能不全。而干预固有免疫反应是否通过减轻微血管功能障碍而改善DbCM尚不明确。未来还需更多的研究寻找有关干预固有免疫反应治疗DbCM的具体机制。Diabetic cardiomyopathy(DbCM)is a metabolic cardiomyopathy with persistent low-grade inflammation induced by insulin secretion deficiency and/or insulin resistance accompanied by glycolipid metabolism disorder,which eventually develops into heart failure.The incidence of this disease is increasing year by year in China,and the clinical efficacy of drugs is very limited.With the further study,it is found that microvascular dysfunction mediated by innate immune response and abnormal apoptosis of cardiomyocytes accelerate the progression of DbCM,and intervention of innate immune response can alleviate the heart dysfunction caused by diabetes.It is not clear whether intervention of innate immune response can improve DbCM by alleviating microvasculardysfunction.More studies are needed in the future to find out the specific mechanism of intervening innate immune response in the treatment of DbCM.

关 键 词：糖尿病心肌病 固有免疫 微血管功能障碍 代谢紊乱 

分 类 号：R541[医药卫生—心血管疾病] R543[医药卫生—内科学]